Selection of mutant µplasmin for amyloid-β cleavage in vivo.

Scientific Reports
Dongying YangXinli Lin

Abstract

One of the main culprits of Alzheimer's disease (AD) is the formation of toxic amyloid-β (Aβ) peptide polymers and the aggregation of Aβ to form plaques in the brain. We have developed techniques to purify the catalytic domain of plasmin, micro-plasmin (µPlm), which can be used for an Aβ-clearance based AD therapy. However, in serum, µPlm is irreversibly inhibited by its principal inhibitor α2-antiplasmin (α2-AP). In this study, we engineered and selected mutant forms of µPlm that are both catalytically active and insensitive to α2-AP inhibition. We identified surface residues of μPlm that might interact and bind α2-AP, and used an alanine-scanning mutagenesis method to select residues having higher activity but lower α2-AP inhibition. Then we employed saturation mutagenesis for further optimize both properties. Modeled complex structure of µPlm/α2-AP shows that F587 is a critical contact residue, which can be used as a starting position for further investigation.

References

Oct 1, 1979·European Journal of Biochemistry·S A Cederholm-WilliamsD Collen
Apr 10, 1992·Science·J A Hardy, G A Higgins
Jan 1, 1981·Methods in Enzymology·K W JacksonJ Tang
Jul 1, 1996·Pharmaceutical Research·O B KinstlerM J Treuheit
Nov 10, 1998·Nature Structural Biology·C T Esmon, T Mather
Sep 25, 2002·Journal of Neuroscience Research·H Michael TuckerSteven Estus
Nov 5, 2002·Annual Review of Pharmacology and Toxicology·Dennis J Selkoe, Dale Schenk
Nov 24, 2004·Cellular and Molecular Life Sciences : CMLS·H Myöhänen, A Vaheri
May 26, 2005·Protein Expression and Purification·F William Studier
Oct 26, 2005·Drug Discovery Today·Francesco M Veronese, Gianfranco Pasut
Aug 31, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·J SebagKwang I Suh
Nov 23, 2006·Protein Expression and Purification·Tao GeGuo-Dong Liang
Jun 19, 2008·Proceedings of the National Academy of Sciences of the United States of America·J Steven JacobsenMenelas N Pangalos
Sep 17, 2008·Journal of Cellular and Molecular Medicine·Antero SalminenAnu Kauppinen
Mar 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Herman MorenoRodolfo R Llinás
Oct 17, 2009·Stroke; a Journal of Cerebral Circulation·Vincent N S ThijsPeter Verhamme
Mar 10, 2010·Current Pharmaceutical Biotechnology·Xinli Lin, Tomomi Umetsu
Dec 8, 2010·Cellular and Molecular Life Sciences : CMLS·Johann Schaller, Simon S Gerber
Jan 11, 2011·Molecular Brain·Yun-wu ZhangHuaxi Xu
Jun 8, 2012·Cold Spring Harbor Perspectives in Medicine·Takaomi Saido, Malcolm A Leissring
Apr 18, 2015·Nucleic Acids Research·Jianyi Yang, Yang Zhang
Mar 1, 2008·Journal of Chemical Theory and Computation·Berk HessErik Lindahl
Mar 31, 2016·EMBO Molecular Medicine·Dennis J Selkoe, John Hardy
Jan 1, 2015·Nature Reviews. Disease Primers·Colin L MastersJeffrey L Cummings
Sep 30, 2017·Nature Reviews. Neurology·Jun WangYan-Jiang Wang
Aug 18, 2018·Nature Reviews. Drug Discovery·Barry BolandMark J Millan
Sep 8, 2018·Current Medicinal Chemistry·Leide Caroline Dos Santos PicancoLorane Izabel da Silva Hage-Melim
Feb 27, 2019·Neurochemical Research·Nkumbu L SikanyikaSanjaya Kuruppu
Jul 25, 2019·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey CummingsKate Zhong

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Datasets Mentioned

BETA
AAA61253

Methods Mentioned

BETA
size exclusion chromatography
glycosylation
column chromatography

Software Mentioned

GROMACS
TASSER
Erithacus
GraFit

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.